DPYD Testing Policy Published by NHS England and NHS Improvement

Dear all,

(Note – This statement is for England ONLY)

Please find an update from NHS England and NHS Improvement on:

  • Clinical commissioning policy statement for pharmacogenomic testing for DPYD gene polymorphisms prior to initiation of fluoropyrimidine-based chemotherapy treatments

 

 

Dear stakeholder,

NHS England and NHS Improvement has published a clinical commissioning policy statement for pharmacogenomic testing for DPYD gene polymorphisms prior to initiation of fluoropyrimidine-based chemotherapy treatments. This clinical commissioning policy can be accessed here:

https://www.england.nhs.uk/publication/clinical-commissioning-urgent-policy-statement-pharmacogenomic-testing-for-dpyd-polymorphisms-with-fluoropyrimidine-therapies/

The policy outlines that all patients, prior to commencing treatment with a fluoropyrimidine based therapy (5-fluorouracil, capecitabine or tegafur) should be screened for four DPYD variants which have been associated with fluoropyrimidine-associated toxicity, and provides further information on the implementation of this clinical policy.

The benefits of the implementation of this policy for patients include:
• Detection of patients who may be at increased risk of severe and even fatal toxicity in patients receiving fluoropyrimidine treatment
• Dose adjustments for fluoropyrimidine therapy or use of an alternative treatment following detection of a DPYD variant, improving efficacy of treatment and reducing risk of adverse side-effects
• More personalised treatment based on a patients’ unique genetic make-up.

The testing in this service will initially be provided by five Genomic Laboratory Hubs (GLHs) on behalf of the whole country, and move to a model of provision from all seven GLHs by April 2021. Implementation via the NHS Genomic Medicine Service GLHs will ensure that all patients receive equitable access to testing.

The UK Chemotherapy Board have published national consensus clinical guidelines to support treatment decisions following DPYD test results, which can be accessed here https://www.ukchemotherapyboard.org/publications. Further information to support rapid implementation of the policy has been circulated to regional teams, providers and GLHs.

If you have any questions about this policy then please email the NHS England and NHS Improvement Genomics Unit at [email protected]

Kind regards,
The Genomics Unit
NHS England and NHS Improvement

Latest News

By BOPA on 5th August 2022

Don’t miss out, EARLY BIRD RATE until Monday 22nd August 2022

Don’t miss out, EARLY BIRD RATE until Monday 22nd August 2022 Our first in-person meeting in 3 years will be hosted at the world-renowned ACC in Liverpool, set in the…

Read article
By BOPA on 5th August 2022

Community Pharmacist Jackie Lewis – recently featured in the Chemist and Druggist

BOPA’s pioneering Community Pharmacist Jackie Lewis recently featured in the Chemist and Druggist where her work was described critical to the recovery of cancer services post-pandemic.  Jackie is the author…

Read article
By BOPA on 2nd August 2022

Publication update – National SACT regimen specific consent form – Colorectal update

Dear All, The consent form project team is pleased to announce that the colorectal SACT consent forms have been reviewed and updated. They are available on the CRUK website at:…

Read article
By BOPA on 29th July 2022

Message from the BOPA Research Committee

We are delighted to announce that we have received a record-breaking number of abstracts for the 2022 Symposium in Liverpool.  A crack team of markers are now in the process…

Read article

25th BOPA Symposium 2022

7th to 9th October 2022 at The ACC Liverpool

REGISTRATION NOW OPEN!
Members: www.bopa.org.uk/2022-members-symposium-link/
Non members: Contact Media1Productions: [email protected]
Please see Key information before for accommodation information.

DRAFT AGENDA
Please click here to view the latest agenda.

CONFERENCE FEES (includes VAT)
Early-bird rate applies up until Monday 22nd August 2022

Everything you need to know